🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

68 results for “Lxo” Clear

  1. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  4. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  5. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  6. Discontinuation antipsychotic treatment

    Lxo Ireland Designated Activity Company

    Psychosis Nos/Other

    phase 3 small molecule active

    1 trial

  7. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  9. Influenza vaccine

    Lxo Ireland Designated Activity Company

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  10. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  11. Levodopa

    Lxo Ireland Designated Activity Company

    Ischaemic Stroke

    phase 3 small molecule completed

    1 trial

  12. Paclitaxel-releasing PTA balloon catheter

    Lxo Ireland Designated Activity Company

    Arteriovenous Fistula Renal Dialysis Devices Obstruction

    phase 3 other completed

    1 trial

  13. Platelet rich plasma

    Lxo Ireland Designated Activity Company

    Coxarthrosis

    phase 3 small molecule completed

    1 trial

  14. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  15. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Rituximab

    Lxo Ireland Designated Activity Company

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  17. Topotecan - usual

    Lxo Ireland Designated Activity Company

    SCLC

    phase 3 small molecule active

    1 trial

  18. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  19. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  20. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  21. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  22. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  23. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  24. Bioengineered Artificial Mesenchimal Sheet (BAMS)

    Lxo Ireland Designated Activity Company

    Venous Ulcer

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources